Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
Clicks: 256
ID: 115895
2020
Background: Tacrolimus (TAC) is used for the management of ulcerative colitis (UC). However, there are few reports on the effectiveness of its long-term administration. TAC is also known to cause renal toxicity. The aim of this study was to evaluate long-term effectiveness and monitor changes in renal function during prolonged TAC use in patients with UC. Methods: Medical records of 50 UC patients treated with TAC were retrospectively reviewed. Clinical outcomes were assessed at 6, 12, 24, and 36 months after initiating TAC. We also monitored chronological changes in renal function. Results: Thirty-nine patients were treated with TAC for more than 3 months. Relapse-free survival among these patients at 6, 12, 24, and 36 months was 82%, 69%, 41%, and 23%, respectively. On the other hand, renal function was reduced in 35.9% of patients. We found that irreversible renal dysfunction was more likely to occur in cases in which the estimated glomerular-filtration rate (eGFR) was reduced by more than 30%. Conclusion: This study demonstrated the potential use of TAC as an effective option in the long-term medical management of UC, although it tended to increase the risk of nephrotoxicity. There is a need for the careful monitoring of renal function during TAC administration.
Reference Key |
haga2020journaleffectiveness
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | Keiichi Haga;Tomoyoshi Shibuya;Kei Nomura;Koki Okahara;Osamu Nomura;Dai Ishikawa;Naoto Sakamoto;Taro Osada;Akihito Nagahara;Haga, Keiichi;Shibuya, Tomoyoshi;Nomura, Kei;Okahara, Koki;Nomura, Osamu;Ishikawa, Dai;Sakamoto, Naoto;Osada, Taro;Nagahara, Akihito; |
Journal | journal of clinical medicine |
Year | 2020 |
DOI | 10.3390/jcm9061771 |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.